The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Puthalakath, H., Huang, D. C. S., O’Reilly, L. A., King, S. M., & Strasser, A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80456-6 · Cited by 1,054
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Self-citationPharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Wahl, A. F., Donaldson, K. L., Faircnild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., & Galloway, D. A. (1996) · Nature Medicine · doi:10.1038/nm0196-72 · Cited by 646
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · cited 1×
“Two of these models are based on the in vitro transformation of mouse ovarian surface epithelial cells — by either retroviral-mediated oncogene delivery or spontaneous transformation during passage — and their re-implantation into the peritoneal cavity of syngenic mic”
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Statistical aspects of prognostic factor studies in oncology
Simon, R., & Altman, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.192 · Cited by 582
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Self-citationLee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 450
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sørensen, P. G., Hansen, M., Sessa, C., de Swart, C. A. M., Hirsch, F. R., Lund, B., & van Houwelingen, H. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3084 · Cited by 428
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Cancer: Principles and Practice of Oncology
Levi, J. A. (1987) · Pathology · doi:10.1016/s0031-3025(16)39749-5 · Cited by 404
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 384
Cellular and molecular determinants of cisplatin resistance
Perez, R. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00227-5 · Cited by 384
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review
Wang, L. G., Liu, X. M., Kreis, W., & Budman, D. R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050989 · Cited by 373
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system
Orsulic, S., Li, Y., Soslow, R. A., Vitale-Cross, L. A., Gutkind, J. S., & Varmus, H. E. (2002) · Cancer Cell · doi:10.1016/s1535-6108(01)00002-2 · Cited by 358
Bonadonna, G. (1995) · JAMA · doi:10.1001/jama.273.7.542 · Cited by 352
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
Teicher, B., Herman, T., Holden, S., Wang, Y., Pfeffer, M., Crawford, J., & Frei, E. (1990) · Science · doi:10.1126/science.247.4949.1457 · Cited by 327
Croix, B. S., Flørenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., & Kerbel, R. S. (1996) · Nature Medicine · doi:10.1038/nm1196-1204 · Cited by 322
Connolly, D. C., Bao, R., Nikitin, A. Y., Stephens, K. C., Poole, T. W., Xiang, H., Harris, S. S., Vanderhyden, B. C., & Hamilton, T. C. (2003) · PubMed · Cited by 310
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Mechanism of action of rituximab
Cerny, T., Borisch, B., Introna, M., Johnson, P., & Rose, A. L. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200211002-00002 · Cited by 287
Acquired multicellular-mediated resistance to alkylating agents in cancer.
Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., & Kerbel, R. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3294 · Cited by 278
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., & Goldberg, G. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1748 · Cited by 263
Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Self-citationlzquierdo, M. A., Zee, A. G. J. V. D., Vermorken, J. B., Valk, P. V. D., Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1230 · Cited by 220
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3422 · Cited by 208
Scanlon, K. J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J. J., & Kashani-Sabet, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10591 · Cited by 207
Los, G., Mutsaers, P. H. A., van der Vijgh, W. J. F., Baldew, G. S., de Graaf, P. W., & McVie, J. G. (1989) · PubMed · Cited by 205
Ozols, R. F., Louie, K. G., Plowman, J., Behrens, B. C., Fine, R. L., Dykes, D., & Hamilton, T. C. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90392-3 · Cited by 202
Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar, V., Lee, J., Pandita, A., Iturria, S., Avula, R., Staub, J., Morrissey, M., Calhoun, E., Sen, A., Kalli, K., et al. (2001) · PubMed · Cited by 196
Genome changes and gene expression in human solid tumors
Gray, J. W., & Collins, C. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.443 · Cited by 193
Taxol induction of p21WAF1 and p53 requires c-raf-1.
Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Mimnaugh, E. G., Trepel, J. B., & Neckers, L. M. (1995) · PubMed · Cited by 182
Proteasome inhibition: a novel approach to cancer therapy
Adams, J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02315-8 · Cited by 180
Hamilton, T. C., Young, R. C., Louie, K. G., Behrens, B. C., McKoy, W. M., Grotzinger, K. R., & Ozols, R. F. (1984) · PubMed · Cited by 169
Hamilton, T. C., Young, R. C., & Ozols, R. F. (1984) · PubMed · Cited by 168
Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
Lai, G.-M., Ozols, R. F., Young, R. C., & Hamilton, T. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.535 · Cited by 167
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D., & Pegram, M. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700472 · Cited by 164
Toffoli, G., Russo, A. G., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., & Boiocchi, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980417)79:2<121::aid-ijc4>3.0.co;2-v · Cited by 164
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer, P. J., Hamilton, T. C., LaCreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.249 · Cited by 162
Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1193 · Cited by 159
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
O'Dwyer, P. J., LaCreta, F. P., Nash, S., Tinsley, P. W., Schilder, R. J., Clapper, M. L., Tew, K. D., Panting, L., Litwin, S., & Comis, R. L. (1991) · PubMed · Cited by 145
Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
Tomida, A., & TSURUO, T. (1999) · PubMed · Cited by 144
Kunkel, L., Wong, A., Maneatis, T., Nickas, J., Brown, T., Grillo-López, A. J., Benyunes, M., Grobman, B., & Dillman, R. O. (2000) · PubMed · Cited by 144
Farnesyl transferase inhibitors: a novel targeted therapy for cancer
Johnston, S. R. D. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00191-1 · Cited by 141
Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137
Andrews, P. A., Jones, J. A., Varki, N. M., & Howell, S. B. (1990) · Cancer Communications · doi:10.3727/095535490820874641 · Cited by 130
Nehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
Samimi, G., Fink, D. A., Varki, N. M., Husain, A., Hoskins, W. J., Alberts, D. S., & Howell, S. B. (2000) · PubMed · Cited by 128
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
Sandercock, J., Parmar, M., Torri, V., & Qian, W. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600567 · Cited by 128
Sui, L., Dong, Y., Ohno, M., et al. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.2.315 · Cited by 128
Furui, T., LaPushin, R., Mao, M., Khan, H., Watt, S. R., Watt, M. A. V., Lu, Y., Fang, X., Tsutsui, S., Siddik, Z. H., et al. (1999) · PubMed · Cited by 127
Identification of Genes That Mediate Sensitivity to Cisplatin
Niedner, H., Christen, R. D., Lin, X., Kondo, A., & Howell, S. B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1153 · Cited by 126
Relationship of XIST expression and responses of ovarian cancer to chemotherapy.
Huang, K. C., Rao, P. H., Lau, C. C., Heard, É., Ng, S., Brown, C. J., Mok, S. C., Berkowitz, R. S., & Ng, S. W. (2002) · PubMed · Cited by 117
Arts, H., Katsaros, D., de Vries, E. G. E., Massobrio, M., Genta, F. T., Danese, S., Arisio, R., Scheper, R. J., Kool, M., Scheffer, G. L., et al. (1999) · PubMed · Cited by 113
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer
Hengstler, J. G., Lange, J., Kett, A., Dornhöfer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F., & Tanner, B. (1999) · PubMed · doi:10.5167/uzh-113865 · Cited by 106
Pharmacogenetics and cancer chemotherapy
Iyer, L., & Ratain, M. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00230-5 · Cited by 105
Tumor targeting by conjugation of DHA to paclitaxel
Bradley, M. O., Swindell, C. S., Anthony, F. H., Witman, P. A., Devanesan, P. D., Webb, N. L., Baker, S. D., Wolff, A. C., & Donehower, R. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00321-2 · Cited by 101
Seiden, M. V., Swenerton, K. D., Matulonis, U. A., Campos, S., Rose, P. G., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. W., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6762 · Cited by 98
Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer
Mano, Y., Kikuchi, Y., Yamamoto, K., Kita, T., Hirata, J., Tode, T., Ishii, K., & Nagata, I. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00124-0 · Cited by 91
Bavetsias, V., Marriott, J. H., Melin, C., Kimbell, R., Matusiak, Z. S., Boyle, F. T., & Jackman, A. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm991119p · Cited by 91
Luu, Y., Bush, J., Cheung, K. J., & Li, G. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5526 · Cited by 86
du Bois, A., Neijt, J. P., & Thigpen, J. T. (1999) · Annals of Oncology · doi:10.1023/a:1008355317514 · Cited by 85
Šale, S., Sung, R. K., Shen, P., Yu, K. M., Wang, Y. C., Durán, G. E., Kim, J.-H., Fojo, T., Oefner, P. J., & Sikic, B. I. (2002) · PubMed · Cited by 79
Surgical management of ovarian cancer
Mutch, D. G. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31589 · Cited by 77
Adhesion-dependent multicellular drug resistance.
Green, S. K., Frankel, A. E., & Kerbel, R. S. (1999) · PubMed · Cited by 75
Judson, P. L., Jm, W., Pa, G., Wc, F., & Js, H. (1999) · PubMed · Cited by 69
Recent advances in the treatment of epithelial ovarian cancer
Harries, M., & Kaye, S. B. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1715 · Cited by 54
Self-citationSmith‐Sørensen, B., Kærn, J., Holm, R., Dørum, A., Trope, C. G., & Børresen‐Dale, A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.502 · Cited by 54
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
Bartelink, H. G. M. M., Schellens, J. H. M., & Verheij, M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00363-x · Cited by 50
Silvestrini, R., Daidone, M. G., Veneroni, S., Benini, E., Scarfone, G., Zanaboni, F., Villa, A., Presti, M., Danese, S., & Bolis, G. (1998) · Cancer · Cited by 47
Metallothionein levels in ovarian tumours before and after chemotherapy
Murphy, D., McGown, A. T., Crowther, D., Mander, A., & Fox, B. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.160 · Cited by 44
Sequence‐dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo
Milross, C., Peters, L. J., Hunter, N. R., Mason, K. A., & Milas, L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620518 · Cited by 40
Sheridan, E., Silcocks, P. B. S., Smith, J. H. F., Hancock, B. W., & Goyns, M. H. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00325-y · Cited by 37
Pan, B., Yao, K.-S., Monia, B. P., Dean, N. M., McKay, R. A., Hamilton, T. C., & O'Dwyer, P. J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00841-9 · Cited by 34
ET-743: more than an innovative mechanism of action.
Scotto, K. W. (2002) · PubMed · Cited by 29
Thames, H. D., Petersen, C., Petersen, S., Nieder, C., & Baumann, M. A. (2002) · Strahlentherapie und Onkologie · doi:10.1007/s00066-002-0923-x · Cited by 27
du Bois, A., Neijt, J. P., & Thigpen, J. T. (1999) · Annals of Oncology · doi:10.1016/s0923-7534(20)31482-4 · Cited by 26
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Metadata
- Authors
- Agarwal, R., & Kaye, S. B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 502-516
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2115954319
- Cited by
- 1,154
- References
- 117
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.